We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (6039)5/6/2021 11:06:36 PM
From: robert b furman  Read Replies (1) | Respond to of 6544
Hi Rick,

Good to see you paying attention. LOL

Been busy myself!


To: richardred who wrote (6039)5/26/2021 9:07:21 AM
From: richardred  Read Replies (1) | Respond to of 6544
Added to MDWD yesterday. The fear of an impending delay of NexoBrid linger. However Hypothetically maybe they can find a new partner for phase two candidate EscharEx. Partners such as Smith&Nephew or GSK ?

P.S. Interesting new application candidate in very early stages.

The phase II investigator-initiated trial is an open-label study, designed to evaluate the safety and efficacy of MWPC005 in removing non-melanoma skin cancer and pre-cancerous lesions (e.g. actinic keratosis, BCC and squama cell carcinoma) in up to 50 patients.

About MWPC005

MWPC005, is a topically applied biological product candidate based on the same active substance as in NexoBrid® and EscharEx® products, a concentrate of proteolytic enzymes enriched in Bromelain. MWPC005 is based on a proprietary formulation, designed to ease self-administration by the patients. The clinical development plan of MWPC005 is supported by the results from several toxicological and other preclinical studies, as well as the vast clinical experience from NexoBrid and EscharEx, which share the same active substance.

To: richardred who wrote (6039)6/11/2021 11:09:54 AM
From: richardred  Read Replies (1) | Respond to of 6544
Added to ENZ today after the recently announced good earnings were scoffed on. The retained investment bankers Cain brothers made a recent transaction with Quest.-DGX With over a billion in cash. I'm sure they have money left over from the Quest transaction should they be interested in ENZ?

Cain brothers recently completed this transaction. Mercy has sold its Outreach Laboratory Services business to Quest Diagnostics.